Find your path to Nigel
67 people in our graph share verified history with Nigel — schools, employers, funds. One of them is your warm intro.
Omar El-KhalafunlockedNigel: together at Versant Ventures (2023–2026)
×11Nigel: together at Versant Ventures
About
Nigel Sheail is a Versant partner based in Basel with over two decades of pharmaceutical leadership experience. He previously served as Global Head of M&A and Business Development & Licensing at Novartis, and held business development and M&A leadership roles at Bayer Healthcare and Roche.
Contact· self-published, not guessed
Experience
- Versant VenturesVenture Partnercurrent2023 — present
- NovartisHead of BDandL Novartis2015 — 2023Basel und Umgebung, Schweiz
Skills & more
Biopharmaceuticals14Biotechnology17Drug Development9Pharmaceutical Industry19
From Nigel's professional profile.
Colleagues at Versant Ventures
Alex Mayweg
Managing Director at Versant Ventures
Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Venture Advisor at Intuitive Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures
Frequently asked questions
- Who is Nigel Sheail?
- Nigel Sheail is a Versant partner based in Basel with over two decades of pharmaceutical leadership experience. He previously served as Global Head of M&A and Business Development & Licensing at Novartis, and held business development and M&A leadership roles at Bayer Healthcare and Roche.
- Where does Nigel Sheail work?
- Nigel Sheail is Partner at Versant Ventures.
Shared employers
Also worked at Novartis327
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 321 more